138 related articles for article (PubMed ID: 28645089)
1. Drug Resistance Mechanism of L10F, L10F/N88S and L90M mutations in CRF01_AE HIV-1 protease: Molecular dynamics simulations and binding free energy calculations.
Vasavi CS; Tamizhselvi R; Munusami P
J Mol Graph Model; 2017 Aug; 75():390-402. PubMed ID: 28645089
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations.
Ode H; Matsuyama S; Hata M; Hoshino T; Kakizawa J; Sugiura W
J Med Chem; 2007 Apr; 50(8):1768-77. PubMed ID: 17367119
[TBL] [Abstract][Full Text] [Related]
3. Exploring the drug resistance mechanism of active site, non-active site mutations and their cooperative effects in CRF01_AE HIV-1 protease: molecular dynamics simulations and free energy calculations.
C S V; Tamizhselvi R; Munusami P
J Biomol Struct Dyn; 2019 Jul; 37(10):2608-2626. PubMed ID: 30051758
[TBL] [Abstract][Full Text] [Related]
4. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
5. Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S.
Bihani SC; Das A; Prashar V; Ferrer JL; Hosur MV
Biochem Biophys Res Commun; 2009 Nov; 389(2):295-300. PubMed ID: 19720046
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
7. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
Soares RO; Batista PR; Costa MG; Dardenne LE; Pascutti PG; Soares MA
J Mol Graph Model; 2010 Sep; 29(2):137-47. PubMed ID: 20541446
[TBL] [Abstract][Full Text] [Related]
8. The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways.
Bandaranayake RM; Kolli M; King NM; Nalivaika EA; Heroux A; Kakizawa J; Sugiura W; Schiffer CA
J Virol; 2010 Oct; 84(19):9995-10003. PubMed ID: 20660190
[TBL] [Abstract][Full Text] [Related]
9. Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.
Ode H; Ota M; Neya S; Hata M; Sugiura W; Hoshino T
J Phys Chem B; 2005 Jan; 109(1):565-74. PubMed ID: 16851048
[TBL] [Abstract][Full Text] [Related]
10. Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors.
Bastys T; Gapsys V; Walter H; Heger E; Doncheva NT; Kaiser R; de Groot BL; Kalinina OV
Retrovirology; 2020 May; 17(1):13. PubMed ID: 32430025
[TBL] [Abstract][Full Text] [Related]
11. Molecular Dynamics Simulations of HIV-1 Protease Suggest Different Mechanisms Contributing to Drug Resistance.
Wartha F; Horn AH; Meiselbach H; Sticht H
J Chem Theory Comput; 2005 Mar; 1(2):315-24. PubMed ID: 26641303
[TBL] [Abstract][Full Text] [Related]
12. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
13. Systematic molecular dynamics, MM-PBSA, and ab initio approaches to the saquinavir resistance mechanism in HIV-1 PR due to 11 double and multiple mutations.
Tzoupis H; Leonis G; Avramopoulos A; Mavromoustakos T; Papadopoulos MG
J Phys Chem B; 2014 Aug; 118(32):9538-52. PubMed ID: 25036111
[TBL] [Abstract][Full Text] [Related]
14. Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation.
Liu X; Xiu Z; Hao C
J Comput Aided Mol Des; 2009 May; 23(5):261-72. PubMed ID: 19219633
[TBL] [Abstract][Full Text] [Related]
15. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection.
Ariyoshi K; Matsuda M; Miura H; Tateishi S; Yamada K; Sugiura W
J Acquir Immune Defic Syndr; 2003 Jul; 33(3):336-42. PubMed ID: 12843744
[TBL] [Abstract][Full Text] [Related]
16. Revealing the drug resistance mechanism of saquinavir due to G48V and V82F mutations in subtype CRF01_AE HIV-1 protease: molecular dynamics simulation and binding free energy calculations.
C S V; Munusami P
J Biomol Struct Dyn; 2023 Feb; 41(3):1000-1017. PubMed ID: 34919029
[TBL] [Abstract][Full Text] [Related]
17. Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.
Prashar V; Bihani SC; Ferrer JL; Hosur MV
Chem Biol Drug Des; 2015 Sep; 86(3):302-8. PubMed ID: 25487655
[TBL] [Abstract][Full Text] [Related]
18. The impact of active site mutations of South African HIV PR on drug resistance: Insight from molecular dynamics simulations, binding free energy and per-residue footprints.
Ahmed SM; Maguire GE; Kruger HG; Govender T
Chem Biol Drug Des; 2014 Apr; 83(4):472-81. PubMed ID: 24267738
[TBL] [Abstract][Full Text] [Related]
19. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
20. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.
Mitsuya Y; Winters MA; Fessel WJ; Rhee SY; Hurley L; Horberg M; Schiffer CA; Zolopa AR; Shafer RW
AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1300-5. PubMed ID: 17209774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]